Synta Pharmaceuticals to Present Interim Results from the GALAXY Trial at ESMO 2012
9/18/2012 9:56:49 AM
LEXINGTON, Mass.--(BUSINESS WIRE)--Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that interim results from the Company’s Phase 2b/3 GALAXY Trial will be presented at the European Society of Medical Oncology 2012 Congress held in Vienna, Austria from September 28 to October 2, 2012. The poster, “The GALAXY Trial (NCT01348126): A randomized IIB/III study of ganetespib (STA-9090) in combination with docetaxel versus docetaxel alone as second line therapy in patients with stage IIIB or IV NSCLC,” will be presented by Suresh Ramalingam, MD, Associate Professor, Hematology & Medical Oncology, and Director, Translational Thoracic Malignancies Program, of the Winship Cancer Institute of Emory University. The poster session is scheduled to take place on Saturday, September 29, 2012 from 1:00 p.m. to 2:00 p.m. (local time).
comments powered by